OA inhibited mitophagy by reducing TFAM, which supported the idea that TFAM is essential for in mitochondrial quality control when the combination of sorafenib and OA might potentially exacerbate mitochondrial dysfunction and oxidative stress, which could create a synergistic effect, enhancing tumor cell death. Here, TFAM is linked to neoplasm.